慢性淋巴细胞白血病中HERV-K与胚胎基因的表达及其与治疗方案的相关性
研究检测49例健康供者和74例慢性淋巴细胞白血病(CLL)患者外周血单个核细胞中HERV与胚胎基因的表达,发现患者表达高于健康供者且随治疗状态不同,在伊布替尼治疗患者中HERV与CLL不良预后因素相关,作者认为可能作为监测创新治疗的潜在生物标志物但需更大队列确认。
要点
- CLL患者HERV与胚胎基因表达高于健康供者,且按治疗状态呈现不同表达。
- 主成分分析显示HERV与胚胎基因的复杂表达谱与CLL及不同治疗方案相关。
- 伊布替尼治疗患者中HERV与CLL不良预后因素相关。
核心结论
- 研究结果虽需在更大患者队列中确认,但突显了CLL中HERV与胚胎基因的相互关联,提示其可作为监测创新治疗的潜在新生物标志物。
研究设计与样本
- 研究纳入49例健康供者和74例CLL患者,分离外周血单个核细胞,采用实时聚合酶链反应分析不同HERV与胚胎基因的表达,并评估患者治疗方案。
主要发现
- 分子分析显示CLL患者的HERV与胚胎基因表达高于健康供者,且按治疗状态呈现不同表达。
- 主成分分析发现HERV与胚胎基因的复杂表达谱与CLL及不同治疗方案相关。
- 在伊布替尼治疗患者中,HERV与CLL不良预后因素相关。
局限性
- 原文指出这些发现需在更大患者队列中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulated expression of human endogenous retrovirus K (HERV-K) has been found in many types of tumors. Previously, we demonstrated the concomitant expression of HERVs and embryonic genes in cancer cells with aggressive and stemness features. In the field of onco-hematology, some studies have described alterations of HERV expression in chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world. Despite numerous achievements in CLL clinical research, given the heterogeneity of the disease and the different treatment choices, identification of new biomarkers for patient management is needed. On this basis, this work aimed to evaluate the expression of HERVs and embryonic genes as novel combined biomarkers in CLL and their potential association with clinical features and therapy regimens. Peripheral blood mononuclear cells were isolated from 49 healthy donors (HDs) and 74 patients with CLL, evaluating their treatment regimen. The expression of different HERVs and embryonic genes was analyzed by real-time polymerase chain reaction. Molecular analysis showed higher expression of HERVs and embryonic genes in patients than HDs, differently expressed according to treatment status. Using principal component analysis, we found complex expression profiles of HERVs and embryonic genes associated with CLL and different treatment regimens. In ibrutinib-treated patients, HERVs were found to be associated with unfavorable prognostic factors of CLL. These findings, although requiring confirmation in larger patient cohorts, highlight the interconnection between HERVs and embryonic genes in CLL, suggesting their use as potential new biomarkers in monitoring innovative treatments.
引用
- Matteucci C, Petrone V, Giovinazzo A, et al. Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens. Blood Adv. 2025. PMID: 40493879. doi:10.1182/bloodadvances.2024014181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。